Expanding Treatment Options: The Latest Developments in COPD - Episode 15
The MD Magazine Peer Exchange “Expanding Treatment Options: The Latest Developments in COPD Therapy” features a panel of physician experts discussing key topics in COPD therapy, including risk factors, personalized treatment, preventive measures, new combination therapies, and more.
This Peer Exchange is moderated by Peter Salgo, MD, professor of medicine and anesthesiology at Columbia University and an associate director of surgical intensive care at the New York-Presbyterian Hospital in New York City.
The panelists are:
There are many new classes of drugs in development for COPD, but Hanania indicated that many of these investigational therapies have been found to be disappointingly ineffective, possibly due to the disease’s heterogeneity. MAP38 kinase inhibition, which makes logical sense as a pathway to target, but it has resulted in many systemic side effects so far.
One of the issues with developing new drugs for COPD, said Thomashow, is the lack of biomarkers that could serve as end points in COPD.